North America Injectable Drug Delivery Market (2019 to 2027) – CAGR of 7.61% Estimated During the Forecast Period – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Injectable Drug Delivery Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering.

This report on the injectable drug delivery market in North America estimates the market to grow at a CAGR of 7.61% in the forecast period.

The United States and Canada together constitute the North American injectable drug delivery market. Since the countries in North America are technologically advanced with better quality healthcare infrastructure, high revenue is generated from the region as compared to others. North America ranks second in the revenue generation in the injectable drug delivery system market, with the US being the highest contributor.

The increase in the number of cancer patients, coupled with the demand for better and effective treatment, is the main factor in boosting the demand for injectable drug delivery technology in Canada over the forecasted period. Rising cases of chronic diseases such as diabetes and arthritis are anticipated to encourage self-administration of drugs, thereby increasing the demand for injectable drug delivery systems. The introduction of nanoparticle-based drug delivery systems has gained huge popularity and encouragement in cancer treatments. Nanoparticles, a component of nanomedicines, are considered as one of the promising drug delivery systems for cancer treatment. The increase in the adaptability of the biologics and its development will instigate the market growth of the injectable drug delivery systems.

Various research and developments on the injectable drug delivery technology have been conducted in Canada following the ongoing biologics sector advancement. For example, the University of Toronto Lab has created orally absorbable molecules, derived from peptides that can be used in the cases of irritable bowels.

Key Topics Covered:

1. North America Injectable Drug Delivery Market – Summary

2. Industry Outlook

2.1. Market Definitions

2.2. Porter’s Five Forces Model

2.2.1. Threat of New Entrant

2.2.2. Threat of Substitute

2.2.3. Bargaining Power of Buyers

2.2.4. Bargaining Power of Suppliers

2.2.5. Intensity of Competitive Rivalry

2.3. Market Share Outlook

2.4. Key Insight

2.5. Key Buying Criteria

2.6. Legal Requirement

2.7. Regulatory Framework

2.8. Market Attractiveness Index

2.9. Market Drivers

2.9.1. Increasing Geriatric Population

2.9.2. Technological Advancement

2.9.3. Growing Occurrence of Autoimmune Diseases

2.10. Market Restraint

2.10.1. High Manufacturing Cost of the Injectable Drug Delivery

2.11. Market Opportunity

2.11.1. Development of Better Injectable Systems

2.12. Market Challenges

2.12.1. Developments in the Alternate Drug Delivery System

2.12.2. Stringent Regulations

3. Injectable Drug Delivery Market Outlook – by Device Type

3.1. Pen Injector

3.2. AutoInjector

3.3. Needle-Free Injector

3.4. Prefilled Syringe

4. Injectable Drug Delivery Market Outlook – by Route of Administration

4.1. Subcutaneous

4.2. Intramuscular

4.3. Intravenous (IV)

4.4. Other Route of Administration

5. Injectable Drug Delivery Market Outlook – by End-User

5.1. Clinics/Physician Offices

5.2. Ambulatory Care

5.3. Hospital

5.4. Home Based

5.5. Others End-User

6. Injectable Drug Delivery Market – North America

6.1. Country Analysis

6.1.1. The United States

6.1.2. Canada

7. Company Profiles

7.1. Baxter

7.2. Becton, Dickinson and Company (BD)

7.3. Elcam Medical

7.4. Eli Lilly and Company

7.5. Gerresheimer

7.6. Injex

7.7. Novartis AG

7.8. Novo Nordisk A/S

7.9. Pfizer Inc.

7.10. Sanofi

7.11. Schott AG

7.12. Terumo Corporation

7.13. Teva Pharmaceutical Industries Ltd.

7.14. West Pharmaceutical Services, Inc.

7.15. Ypsomed

8. Research Methodology & Scope

8.1. Research Scope & Deliverables

8.1.1. Objectives of Study

8.1.2. Scope of Study

8.2. Sources of Data

8.2.1. Primary Data Sources

8.2.2. Secondary Data Sources

8.3. Research Methodology

8.3.1. Evaluation of Proposed Market

8.3.2. Identification of Data Sources

8.3.3. Assessment of Market Determinants

8.3.4. Data Collection

8.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/4ug6or

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900